Oral formulations of the selective serotonin3 antagonists ramosetron (intraoral disintegrator formulation) and granisetron hydrochloride (standard tablet) in treating acute chemotherapy-induced emesis, nausea, and anorexia: A multicenter, randomized, single-blind, crossover, comparison study

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 11, 2002, Pages 725-735

  Feng, Feng Yi ^a   Zhang, Pin ^a   He, You Jian ^b   Li, Yu Hong ^b   Zhou, Mei Zhen ^c   Cheng, Gang ^c   Chen, Yan ^c   Kikkawa, Tomoko ^d   Yamamoto, Minoru ^d  

^a CANCER HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c BEIJING HOSPITAL   (China)

^d ASTELLAS PHARMA INC   (Japan)

Author keywords

5 HT3 antagonist; Anorexia; Chemotherapy; Emesis; Granisetron; Intraoral disintegrator formulation; Nausea; Ramosetron

Indexed keywords

CISPLATIN; DOXORUBICIN; GRANISETRON; RAMOSETRON;

ABDOMINAL DISTENSION; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISPERSIBLE TABLET; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLUSHING; HEADACHE; HUMAN; INSOMNIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM CANCER; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; STOMACH CANCER; TASTE DISORDER; TESTIS CANCER; VERTIGO; XEROSTOMIA;

EID: 0036866994     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80093-5     Document Type: Article

References (27)

1. 3 receptor agonists in the cat: Effect of vagotomy, splanchnicectomy or area postrema lesion. J Pharmacol Exp Ther. 1992;260:509-517.
2. Kamato T, Ito H, Nagakura Y, et al. Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets. Eur J Pharmacol. 1993;238:369-376.
3. 3 receptor antagonist, and its enantiomer in the isolated tissue. J Pharmacol Exp Ther. 1991;259:15-21.
4. 3 receptor antagonist, in rabbit nodose ganglion and N1E-115 neuroblastoma cells. J Pharmacol Exp Ther. 1992;263:1127-1132.
5. 3 receptor antagonist, on 5-HT-induced Bezold-Jarisch reflex in ferrets. The Clin Rep. 1994;28:2329-2335.
6. 3 receptor antagonist, on cisplatin-induced emesis in ferrets. The Clin Rep. 1994;28:2337-2347.
7. 3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea, and anorexia: A single-blind, randomized, crossover study. Curr Ther Res Clin Exp. 2000;61:901-909.
8. Kang YK, Park YH, Ryoo BY, et al. Ramosetron for the prevention of cisplatininduced acute emesis: A prospective randomized comparison with granisetron. J Int Med Res. 2002;30:220-229.
9. Ariyoshi Y, Ota K, Taguchi T, et al. Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo [in Japanese]. Gan To Kagaku Ryoho. 1992;19:2057-2070.
10. 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990;322:816-821.
11. Hesketh PJ, Murphy WK, Lester EP, et al. GR 38032F (GR-C507/75): A novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol. 1989;7:700-705.
12. 3 receptor blocking activities of YM060, a novel 4,5,6,7-tetrahydrobenzimidazole derivative, and its enantiomer in anesthetized rats. J Pharmacol Exp Ther. 1991;259:815-819.
13. 3 receptor antagonist, on cisplatin-induced emesis in the ferret. Clin Pharmacol Ther. 1996;6:1215-1220.
14. Noda K, Ikeda M, Ichijyou M, et al. Early phase II clinical study of ramosetron oral formulation in the treatment of nausea and vomiting caused by cisplatin administration [in Japanese]. J New Remedies Clin. 1996;45:482-490.
15. Noda K, Ikeda M, Taguchi T, et al. Late phase II clinical study of ramosetron oral formulation in the treatment of nausea and vomiting caused by cisplatin administration [in Japanese]. J New Remedies Clin. 1996;45:1309-1321.
16. Poon RT, Chow LW. Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: A randomized crossover study. Br J Cancer. 1998;77:1683-1685.
17. Suminaga M, Furue H, Ohta K, et al. Clinical evaluation of granisetron for nausea and vomiting induced by anticancer drugs - Multi-centered placebo-controlled double-blind comparative study [in Japanese]. Gan To Kagaku Ruyoho. 1993;20:1211-1219.
18. Noda K, Ikeda M, Yoshida O, et al. Clinical phase III study of YM060 injection on anti-cancer drug-induced nausea and vomiting. Double blind comparative study versus placebo. Jpn J Clin Exp Med. 1994;71:2765-2776.
19. Noda K, Ikeda M, Yoshida O, et al. Clinical phase III study of YM060 injection on anti-cancer drug, cisplatin-induced nausea and vomiting. Med Cons New-Remed. 1994;43:2241-2255.
20. Furue H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs: Optimal dose-finding study. J Ther Clin Med. 1990;6(Suppl 5):49-61.
21. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomised, parallel-group study. Oncology. 1994;51:113-118.
22. Noda K, Ikeda M, Taguchi T, et al. Phase III study of oral YM060 on anticancer drug cisplatin-induced nausea and vomiting. J New Remedies Clin. 1996;45:1445-1462.
23. Taketani Y, Yoshikawa H, Kinoshita K, et al. Phase III clinical study of ramosetron oral preparation in the treatment of nausea and vomiting induced by anticancer drugs - Evaluation of usefulness after single oral administration. Obstet Gynecol (Tokyo). 1996;63:129-140.
24. Taketani Y, Yoshikawa H, Kinoshita K, et al. Phase III clinical study of ramosetron oral preparation in the treatment of nausea and vomiting induced by anticancer drugs - Evaluation of usefulness during repeated oral administrations. The World of Obstetrics and Gynecology. 1996;48:749-760.
25. Sicuteri F, Testic A, Anselmi B, et al. Biochemical investigation in headache: Increase in hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy. 1961;19:55-58.
26. 14Cramosetron hydrochloride to rats. Xenobio Metabol Dispos. 1995;10:808-818.
27. Huang CT, Chen KC, Chen CF, Tsai TH. Simultaneous measurement of blood and brain microdialysates of granisetron in rat by high-performance liquid chromatography with fluorescence detection. J Chromotogr B Biomed Sci Appl. 1998;716:251-255.